The effects of GLP-1RAs on multiple human organizations, source: reference [2] Data from Novo Nordisk's Phase III clinical trial showed that liraglutide 3.0 mg resulted in a 5% weight loss in approximately 62% of obese patients and a 10% weight loss in 34% of patients after a 56-week treatment period
Hypersensitivity reactions, including anaphylaxis, anaphylactoid reactions, angioedema, rash, and urticaria, have been reported postmarketing with use of semaglutide
Glucagon-like peptide-1 (GLP-1) agonists are a type of drug used to treat type 2 diabetes mellitus (T2DM) and obesity
Quantitative BBB penetration differs by molecule and remains an active research area
Your Found care team stays with you every month to adjust your plan as your body changes
They work on the biology of appetite rather than trying to override it through willpower alone